Dana Flanders
Stock Analyst at Guggenheim
(n/a)
# 4,626
Out of 4,876 analysts
9
Total ratings
n/a
Success rate
-29.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
VALN Valneva SE | Maintains: Buy | $17 → $15 | $5.81 | +158.18% | 1 | Mar 24, 2025 | |
SCYX SCYNEXIS | Initiates: Buy | $25 | $0.69 | +3,516.37% | 1 | Jan 22, 2021 | |
PCRX Pacira BioSciences | Initiates: Neutral | n/a | $23.48 | - | 1 | May 27, 2020 | |
HRTX Heron Therapeutics | Initiates: Buy | $24 | $2.14 | +1,021.50% | 1 | May 27, 2020 | |
COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $29.93 | - | 1 | May 27, 2020 | |
LGND Ligand Pharmaceuticals | Initiates: Neutral | n/a | $113.99 | - | 2 | Mar 10, 2020 | |
EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $6.35 | +1,081.10% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $5.81
Upside: +158.18%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $0.69
Upside: +3,516.37%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $23.48
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $2.14
Upside: +1,021.50%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $29.93
Upside: -
Ligand Pharmaceuticals
Mar 10, 2020
Initiates: Neutral
Price Target: n/a
Current: $113.99
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $6.35
Upside: +1,081.10%